Xu et al. [30] used a quantitative proteomics approach to identify the major target of the tetrahydroisoquinoline-based compound 24 (DR) as a selective DDR1 inhibitor (IC50 21 nM) with cathepsin D as a major off-target protein in cancer cells (Figure 4). Here, DDR1 is linked to cancer.